Caffeine
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
- Caffeine
- Pharmacist Assessment Report
- Caffeine: adenosine receptor antagonist and phosphodiesterase inhibitor → nasal cavity disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Caffeine: adenosine receptor antagonist and phosphodiesterase inhibitor → nasal cavity disease
One-Sentence Summary
Caffeine is a methylxanthine that acts as an adenosine receptor antagonist and phosphodiesterase inhibitor. The TxGNN model predicts it may be useful for nasal cavity disease, but there are currently no registered clinical trials and only 3 indirectly related publications, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Caffeine is generally known as a methylxanthine that blocks adenosine receptors and inhibits phosphodiesterase. These actions could in principle influence inflammation and airway tone.
One indirect line of reasoning involves bitter taste receptors (TAS2Rs), which are found in the human airway and nasal epithelium. They respond to caffeine-like compounds and may affect ciliary beating and innate defence. A nasal caffeine gel has been studied in a preclinical formulation study, but for cognition after sleep deprivation, not for nasal disease.
The high score probably reflects the model’s proximity to other upper-airway conditions rather than new evidence. The link between caffeine and nasal disease is plausible but unproven.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the publications below studies nasal cavity disease as a treatment target for caffeine.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26272040 | 2015 | Review | Pharmacology & Therapeutics | Bitter taste receptors are expressed in the nasal cavity and lungs, among other tissues, and their pharmacology and role in human airways are reviewed |
| 35579146 | 2022 | Preclinical formulation study | Current Drug Delivery | Thermo-sensitive nasal caffeine in situ gel evaluated for cognition after sleep deprivation, not for nasal disease |
| 9751618 | 1998 | Animal study | Cancer Research | Black tea and caffeine inhibited lung tumour formation in rats given a tobacco-specific carcinogen |
Canada Market Information
The list may be partial. The licence records available here do not include dosage form or approved indication text.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02496771 | PEYONA | Not recorded | Not recorded |
| 02526751 | CAFFEINE CITRATE ORAL SOLUTION USP | Not recorded | Not recorded |
| 02526778 | CAFFEINE CITRATE INJECTION USP | Not recorded | Not recorded |
| 02254468 | TYLENOL ULTRA RELIEF | Not recorded | Not recorded |
| 02544687 | EXTRA STRENGTH TYLENOL DAYTIME RELIEF | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 75 interactions are recorded. Examples include major interactions with nasal and topical cocaine, and moderate interactions with alosetron, obeticholic acid, adenosine, anagrelide, bendamustine, capmatinib, ciprofloxacin, cycloserine, dipyridamole and duloxetine.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but no clinical trial or publication directly studies caffeine in nasal cavity disease. The evidence level is therefore L5 and the prediction is hypothesis-generating only.
To proceed, the following is needed:
- Mechanism of action data for caffeine
- Preclinical or clinical studies of caffeine in nasal or upper-airway disease, such as the effect of bitter taste receptors on nasal epithelium
- Review of the package insert warnings and contraindications, including cardiovascular and stimulant effects
- Evaluation of a suitable route and formulation, since no route compatibility data are available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.